NO173740C - Fremgangsmaate for fremstilling av et rekombinant Cys125-mutert IL-2 - Google Patents

Fremgangsmaate for fremstilling av et rekombinant Cys125-mutert IL-2

Info

Publication number
NO173740C
NO173740C NO833793A NO833793A NO173740C NO 173740 C NO173740 C NO 173740C NO 833793 A NO833793 A NO 833793A NO 833793 A NO833793 A NO 833793A NO 173740 C NO173740 C NO 173740C
Authority
NO
Norway
Prior art keywords
cys125
mutant
recombinant
procedure
preparation
Prior art date
Application number
NO833793A
Other languages
English (en)
Norwegian (no)
Other versions
NO173740B (no
NO833793L (no
Inventor
David F Mark
Leo S Lin
Shi-Da Yu Lu
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27030446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO173740(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of NO833793L publication Critical patent/NO833793L/no
Priority to NO922964A priority Critical patent/NO306951B1/no
Publication of NO173740B publication Critical patent/NO173740B/no
Publication of NO173740C publication Critical patent/NO173740C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO833793A 1982-10-19 1983-10-18 Fremgangsmaate for fremstilling av et rekombinant Cys125-mutert IL-2 NO173740C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO922964A NO306951B1 (no) 1982-10-19 1992-07-27 DNA-sekvens som koder for et modifisert human-IFM-(beta) samt fremgangsmåte for fremstilling derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43515482A 1982-10-19 1982-10-19
US48616283A 1983-04-15 1983-04-15

Publications (3)

Publication Number Publication Date
NO833793L NO833793L (no) 1984-04-24
NO173740B NO173740B (no) 1993-10-18
NO173740C true NO173740C (no) 1994-01-26

Family

ID=27030446

Family Applications (1)

Application Number Title Priority Date Filing Date
NO833793A NO173740C (no) 1982-10-19 1983-10-18 Fremgangsmaate for fremstilling av et rekombinant Cys125-mutert IL-2

Country Status (23)

Country Link
EP (4) EP0192811B1 (de)
JP (2) JPS6128392A (de)
KR (1) KR910009900B1 (de)
AT (4) ATE46539T1 (de)
AU (1) AU563962B2 (de)
BE (1) BE898016A (de)
CA (1) CA1340861C (de)
CH (1) CH669395A5 (de)
DE (4) DE3382528D1 (de)
DK (2) DK168767B1 (de)
ES (4) ES526541A0 (de)
FI (1) FI82266C (de)
FR (1) FR2534594B1 (de)
GB (1) GB2130219B (de)
GR (1) GR79408B (de)
IE (1) IE56026B1 (de)
IL (1) IL69970A (de)
LU (3) LU88761I2 (de)
NL (2) NL930119I2 (de)
NO (1) NO173740C (de)
NZ (1) NZ205922A (de)
PH (2) PH20343A (de)
PT (1) PT77512B (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
ZA844082B (en) * 1983-06-01 1985-09-25 Hoffmann La Roche Polypeptides having interferon activity
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
WO1985004328A1 (en) 1984-03-28 1985-10-10 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
ATE48641T1 (de) * 1984-05-08 1989-12-15 Genetics Inst Ein menschlicher t-zellwachstumsfaktor.
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA1275954C (en) 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
WO1986002068A1 (fr) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
DE3500681A1 (de) * 1985-01-11 1986-07-17 Hoechst Ag, 6230 Frankfurt Verfahren zur isolierung und reinigung von lymphokinen
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
ATE72582T1 (de) * 1986-09-05 1992-02-15 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
EP0298723A1 (de) * 1987-07-07 1989-01-11 California Biotechnology, Inc. Rekombinante Fibroblasten-Wachstumsfaktoren
AU625394B2 (en) * 1987-11-04 1992-07-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Alveolar surfactant proteins
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
CA2003886A1 (en) * 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
EP0456642A1 (de) * 1989-01-31 1991-11-21 The Upjohn Company Somatotropin-analoge
EP0383599B1 (de) * 1989-02-17 1996-02-07 Merck & Co. Inc. Protein-Antikrebsmittel
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5173297A (en) * 1991-07-01 1992-12-22 Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. Bacteriocin from lactococcus lactis subspecies lactis
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
FR2671554A1 (fr) * 1991-01-11 1992-07-17 Clonatec Sa Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE19544167A1 (de) * 1995-11-17 1997-05-22 Schering Ag Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
WO1997048808A1 (en) * 1996-06-19 1997-12-24 Chiron Corporation Bacterial production of interferon-beta using low levels of sodium and potassium ions
CN1100875C (zh) * 1998-03-06 2003-02-05 上海华晨生物技术研究所 新型重组人白细胞介素2的制备方法及其表达载体和工程菌
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AU2002326991A1 (en) * 2001-09-18 2003-04-01 Chiron Corporation Methods for treating multiple sclerosis
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
CN100348618C (zh) 2002-09-11 2007-11-14 弗雷泽纽斯卡比德国有限公司 生产羟烷基淀粉衍生物的方法
EP1549350B1 (de) 2002-10-08 2008-09-24 Fresenius Kabi Deutschland GmbH Pharmazeutisch aktive oligosaccharid-conjugate
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1682178B8 (de) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von krebs mit expression des cd40-antigens
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
EA010501B1 (ru) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
EP1786917A4 (de) * 2004-07-26 2008-05-28 Enzon Pharmaceuticals Inc Optimiertes interferon-beta-gen
GB0523282D0 (en) 2005-11-15 2005-12-21 Isis Innovation Methods using pores
GB2453377A (en) 2007-10-05 2009-04-08 Isis Innovation Transmembrane protein pores and molecular adapters therefore.
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
ES2382058T3 (es) 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
CA2730068A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
EP2682460B1 (de) 2008-07-07 2017-04-26 Oxford Nanopore Technologies Limited Enzym-Pore Konstrukt
US9077937B2 (en) * 2008-11-06 2015-07-07 Alcatel Lucent Method and apparatus for fast channel change
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CA2750874A1 (en) 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Hybridization linkers
CA2750879C (en) 2009-01-30 2018-05-22 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
AU2012215135B9 (en) 2011-02-11 2017-03-09 Oxford Nanopore Technologies Limited Mutant pores
KR102220006B1 (ko) 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
KR20140050067A (ko) 2011-07-25 2014-04-28 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법
GB201119244D0 (en) 2011-11-08 2011-12-21 British American Tobacco Co Smoking article
US9777049B2 (en) 2012-04-10 2017-10-03 Oxford Nanopore Technologies Ltd. Mutant lysenin pores
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
CN105209634B (zh) 2013-03-08 2020-05-12 牛津纳米孔技术公司 酶停滞方法
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
US10183061B2 (en) 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP2918285A1 (de) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 zur Behandlung einer Lebensmittelallergie
CN106459159B (zh) 2014-05-02 2021-11-30 牛津纳米孔技术公司 突变孔
JP7161291B2 (ja) 2014-09-01 2022-10-26 ブイアイビー ブイゼットダブリュ 変異体ポア
EP3204511B1 (de) 2014-10-07 2021-07-28 Oxford Nanopore Technologies Limited Mutante poren
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
US10801023B2 (en) * 2015-04-24 2020-10-13 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
US10876109B2 (en) 2015-04-24 2020-12-29 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
WO2016172445A2 (en) * 2015-04-24 2016-10-27 The University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
AU2016341241B9 (en) 2015-10-22 2021-11-18 Iltoo Pharma Pharmaceutical compositions of IL-2
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
JP7206190B2 (ja) 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
EP3630163A4 (de) 2017-05-24 2021-06-09 Pandion Operations, Inc. Gezielte immuntoleranz
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020102556A1 (en) 2018-11-15 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of prognosis and classification for preeclampsia
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
EP4073094A1 (de) 2019-12-12 2022-10-19 Iltoo Pharma Chimäre interleukin-2-konstrukte
EP4107187A4 (de) 2020-02-21 2024-07-03 Pandion Operations, Inc. Gewebegezielte immuntoleranz mit einem cd39-effektor
JP2023516774A (ja) 2020-03-06 2023-04-20 サントル、オスピタリエ、ユニヴェルシテール、ド、ニーム 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２
WO2021221485A1 (ko) * 2020-04-29 2021-11-04 에이비온 주식회사 이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법
EP4144761A4 (de) * 2020-04-29 2024-05-29 GenoPharm Inc. Rekombinantes protein mit fusioniertem interferon-beta-mutein und -antikörper sowie pharmazeutische zusammensetzung damit
BR112023003614A2 (pt) * 2020-08-28 2023-03-28 Biocad Joint Stock Co Domínio de ligação, ácido nucleico isolado, cassete e vetor de expressão, vírus recombinante e seu uso, composição farmacêutica, vacina baseada em aav5 para indução de imunidade específica ao sars-cov-2 e/ou prevenção de infecção por coronavírus relacionada ao sars-cov-2
EP4412631A1 (de) 2021-10-06 2024-08-14 Iltoo Pharma Chimäre interleukin-2-konstrukte mit targeting von spezifisch für entzündete gewebe
JP7760716B2 (ja) * 2022-05-24 2025-10-27 ジェイ・エイチ・エム バイオファーマシューティカル（ハンチョウ）カンパニー リミテッド 組換えａ型ボツリヌス神経毒及びその調製方法
TW202413442A (zh) 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
KR20250113390A (ko) 2022-09-12 2025-07-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 자폐 스펙트럼 장애 치료에 사용되는 인터루킨-2
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359688A (en) * 1976-11-11 1978-05-29 Tanpakushitsu Kenkiyuu Shiyour Production of novel polypeptide
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE57069B1 (en) * 1980-04-03 1992-04-22 Biogen Inc Dna sequences,recombinant dna molecules and processes for producing human fibroblast interferon
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
ZA844082B (en) * 1983-06-01 1985-09-25 Hoffmann La Roche Polypeptides having interferon activity
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins

Also Published As

Publication number Publication date
IE832380L (en) 1984-04-19
DK168767B1 (da) 1994-06-06
NL960013I1 (nl) 1996-10-01
FR2534594B1 (fr) 1987-06-19
BE898016A (fr) 1984-02-15
ATE46539T1 (de) 1989-10-15
FI82266B (fi) 1990-10-31
ATE73493T1 (de) 1992-03-15
EP0109748A1 (de) 1984-05-30
LU88357I2 (fr) 1994-05-04
AU563962B2 (en) 1987-07-30
ES8505717A1 (es) 1985-04-01
FI82266C (fi) 1991-02-11
DE3382528D1 (de) 1992-04-16
EP0218825A1 (de) 1987-04-22
DE3380598D1 (en) 1989-10-26
FR2534594A1 (fr) 1984-04-20
DK481383D0 (da) 1983-10-19
NO173740B (no) 1993-10-18
EP0192811A1 (de) 1986-09-03
PH23702A (en) 1989-09-27
IE56026B1 (en) 1991-03-27
PT77512A (en) 1983-11-01
EP0234599A1 (de) 1987-09-02
JPH0568480B2 (de) 1993-09-29
CH669395A5 (de) 1989-03-15
EP0218825B1 (de) 1989-09-20
NL930119I1 (nl) 1993-11-01
IL69970A (en) 1991-05-12
LU90413I2 (fr) 1999-09-07
GB8327490D0 (en) 1983-11-16
DK105892A (da) 1992-08-26
DE3382197D1 (de) 1991-04-11
JPS6420096A (en) 1989-01-24
ATE33503T1 (de) 1988-04-15
FI833681L (fi) 1984-04-20
ES8506089A1 (es) 1985-06-16
FI833681A0 (fi) 1983-10-10
ES542829A0 (es) 1986-06-01
EP0192811B1 (de) 1991-03-06
DK481383A (da) 1984-04-20
GB2130219A (en) 1984-05-31
KR840006369A (ko) 1984-11-29
DE3376271D1 (en) 1988-05-19
ES526541A0 (es) 1985-04-01
NO833793L (no) 1984-04-24
NL960013I2 (nl) 1997-03-03
ES8608043A1 (es) 1986-06-01
JPS6128392A (ja) 1986-02-08
EP0234599B1 (de) 1992-03-11
ATE61407T1 (de) 1991-03-15
KR910009900B1 (ko) 1991-12-03
NZ205922A (en) 1987-11-27
DK171681B1 (da) 1997-03-10
EP0109748B1 (de) 1988-04-13
IL69970A0 (en) 1984-01-31
DK105892D0 (da) 1992-08-26
NL930119I2 (nl) 1995-01-16
GB2130219B (en) 1986-01-29
PT77512B (en) 1987-11-24
ES8506801A1 (es) 1985-08-01
AU2008683A (en) 1984-05-03
LU88761I2 (fr) 1996-11-05
ES533053A0 (es) 1985-06-16
PH20343A (en) 1986-12-04
GR79408B (de) 1984-10-22
ES533054A0 (es) 1985-08-01
CA1340861C (en) 1999-12-28

Similar Documents

Publication Publication Date Title
NO173740C (no) Fremgangsmaate for fremstilling av et rekombinant Cys125-mutert IL-2
ATE196298T1 (de) Oberflächenaktives lungenprotein und verwandte polypeptide
DK302388D0 (da) Proteiner
FI102282B1 (fi) Menetelmä O-glykosyloidun IGF-1:n valmistamiseksi
AU5693590A (en) Polypeptide pharmaceutical composition
NO884054D0 (no) Nytt pentapeptid og fremgangsmaate for fremstilling derav.
ATE62598T1 (de) Verzoegerte freisetzung biologisch aktiver somatotropine.
FR2592049B1 (fr) Nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant le calcium de l'organisme, leur preparation et les medicaments contenant ces principes actifs
BG60657B2 (en) Human recombinant interleukin-2 muteins

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN OCTOBER 2003